{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=nivolumab&page=36",
    "query": {
      "intervention": "nivolumab",
      "page": 36
    },
    "page_size": 10
  },
  "pagination": {
    "page": 36,
    "page_size": 10,
    "total_count": 1208,
    "total_pages": 121,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=nivolumab&page=37&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=nivolumab&page=35&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-29T10:44:06.634Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04017650",
      "title": "Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "BRAF NP_004324.2:p.V600E",
        "Metastatic Colon Adenocarcinoma",
        "Metastatic Microsatellite Stable Colorectal Carcinoma",
        "Metastatic Rectal Adenocarcinoma",
        "Progressive Disease",
        "Recurrent Colorectal Carcinoma",
        "Stage III Colorectal Cancer AJCC v8",
        "Stage IIIA Colorectal Cancer AJCC v8",
        "Stage IIIB Colorectal Cancer AJCC v8",
        "Stage IIIC Colorectal Cancer AJCC v8",
        "Stage IV Colorectal Cancer AJCC v8",
        "Stage IVA Colorectal Cancer AJCC v8",
        "Stage IVB Colorectal Cancer AJCC v8",
        "Stage IVC Colorectal Cancer AJCC v8",
        "Unresectable Colon Adenocarcinoma",
        "Unresectable Rectal Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Cetuximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Encorafenib",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 38,
      "start_date": "2019-06-14",
      "completion_date": "2027-12-30",
      "has_results": false,
      "last_update_posted_date": "2026-06-11",
      "last_synced_at": "2026-10-29T10:44:06.634Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04017650"
    },
    {
      "nct_id": "NCT05111574",
      "title": "Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anal Melanoma",
        "Bladder Melanoma",
        "Cervical Melanoma",
        "Esophageal Melanoma",
        "Gallbladder Melanoma",
        "Head and Neck Mucosal Melanoma",
        "Mucosal Melanoma",
        "Nasopharyngeal Mucosal Melanoma",
        "Oral Cavity Mucosal Melanoma",
        "Penile Mucosal Melanoma",
        "Rectal Melanoma",
        "Recurrent Mucosal Melanoma",
        "Sinonasal Mucosal Melanoma",
        "Urethral Melanoma",
        "Urinary System Mucosal Melanoma",
        "Vaginal Melanoma",
        "Vulvar Melanoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Cabozantinib S-malate",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Echocardiography Test",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo Administration",
          "type": "DRUG"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 101,
      "start_date": "2022-08-11",
      "completion_date": "2027-07-15",
      "has_results": false,
      "last_update_posted_date": "2026-08-04",
      "last_synced_at": "2026-10-29T10:44:06.634Z",
      "location_count": 142,
      "location_summary": "Auburn, California • Berkeley, California • Fremont, California + 116 more",
      "locations": [
        {
          "city": "Auburn",
          "state": "California"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Fremont",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05111574"
    },
    {
      "nct_id": "NCT02659059",
      "title": "Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Small-Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Platinum Doublet Chemotherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 324,
      "start_date": "2016-02-15",
      "completion_date": "2022-03-07",
      "has_results": true,
      "last_update_posted_date": "2023-04-05",
      "last_synced_at": "2026-10-29T10:44:06.634Z",
      "location_count": 29,
      "location_summary": "San Diego, California • Plainville, Connecticut • Weston, Florida + 19 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Plainville",
          "state": "Connecticut"
        },
        {
          "city": "Weston",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Savannah",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02659059"
    },
    {
      "nct_id": "NCT03126461",
      "title": "SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma",
        "Metastatic Melanoma"
      ],
      "interventions": [
        {
          "name": "SAbR",
          "type": "RADIATION"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 0,
      "start_date": "2018-03-01",
      "completion_date": "2022-12-31",
      "has_results": false,
      "last_update_posted_date": "2020-08-20",
      "last_synced_at": "2026-10-29T10:44:06.634Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03126461"
    },
    {
      "nct_id": "NCT03141177",
      "title": "A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cabozantinib",
          "type": "DRUG"
        },
        {
          "name": "Sunitinib",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 701,
      "start_date": "2017-07-23",
      "completion_date": "2026-04-01",
      "has_results": true,
      "last_update_posted_date": "2026-08-24",
      "last_synced_at": "2026-10-29T10:44:06.634Z",
      "location_count": 30,
      "location_summary": "Daphne, Alabama • Goodyear, Arizona • Tucson, Arizona + 26 more",
      "locations": [
        {
          "city": "Daphne",
          "state": "Alabama"
        },
        {
          "city": "Goodyear",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03141177"
    },
    {
      "nct_id": "NCT02834247",
      "title": "A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Triple-Negative Breast Neoplasms",
        "Carcinoma, Non-Small-Cell Lung",
        "Head and Neck Carcinoma, Squamous Cell",
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "TAK-659",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Calithera Biosciences, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 41,
      "start_date": "2016-08-12",
      "completion_date": "2018-11-30",
      "has_results": true,
      "last_update_posted_date": "2023-02-08",
      "last_synced_at": "2026-10-29T10:44:06.634Z",
      "location_count": 9,
      "location_summary": "La Jolla, California • Atlanta, Georgia • Boston, Massachusetts + 6 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02834247"
    },
    {
      "nct_id": "NCT07620574",
      "title": "Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cancer",
        "Renal Cell Carcinoma (RCC)",
        "Pancreatic Neuroendocrine Tumors (pNET)",
        "Extra-Pancreatic NET (epNET)",
        "Hepatocellular Carcinoma (HCC)",
        "Differentiated Thyroid Cancer (DTC)",
        "Non-Clear Cell Renal Cell Carcinoma (nccRCC)",
        "Colorectal Cancer",
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Cabozantinib",
          "type": "DRUG"
        },
        {
          "name": "Zanzalintinib",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Abiraterone",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Exelixis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 5000,
      "start_date": "2026-07-30",
      "completion_date": "2030-05-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-28",
      "last_synced_at": "2026-10-29T10:44:06.634Z",
      "location_count": 4,
      "location_summary": "Bay Shore, New York • Kettering, Ohio • Memphis, Tennessee + 1 more",
      "locations": [
        {
          "city": "Bay Shore",
          "state": "New York"
        },
        {
          "city": "Kettering",
          "state": "Ohio"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07620574"
    },
    {
      "nct_id": "NCT02379520",
      "title": "HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Human Papillomavirus-Related Carcinoma",
        "Human Papillomavirus Positive Oropharyngeal Carcinoma",
        "Human Papillomavirus Positive Cervical Carcinoma",
        "Human Papillomavirus Positive Anal Carcinoma",
        "Human Papillomavirus Positive Vulvar Carcinoma",
        "Human Papillomavirus Positive Penile Carcinoma"
      ],
      "interventions": [
        {
          "name": "HPV Specific T Cells",
          "type": "GENETIC"
        },
        {
          "name": "Cytoxan",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2015-09",
      "completion_date": "2026-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-02",
      "last_synced_at": "2026-10-29T10:44:06.634Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02379520"
    },
    {
      "nct_id": "NCT02648997",
      "title": "An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Meningiomas"
      ],
      "interventions": [
        {
          "name": "Nivolumab - 240 mg",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab - 1 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab - 480 mg",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab - 3 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "External Beam RT",
          "type": "RADIATION"
        },
        {
          "name": "Nivolumab - 1 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab - 3 mg/kg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2016-03",
      "completion_date": "2026-10-01",
      "has_results": true,
      "last_update_posted_date": "2026-07-10",
      "last_synced_at": "2026-10-29T10:44:06.634Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02648997"
    },
    {
      "nct_id": "NCT04831320",
      "title": "Nab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 Inhibitor",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Head-and-neck Squamous-cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "nab-paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 46,
      "start_date": "2021-09-28",
      "completion_date": "2028-01-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-06",
      "last_synced_at": "2026-10-29T10:44:06.634Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04831320"
    }
  ]
}